FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164704825> ?p ?o ?g. }

• W3164704825 abstract "Respiratory tract infection with Pseudomonas aeruginosa occurs in most people with cystic fibrosis. Once chronic infection is established, Pseudomonas aeruginosa is virtually impossible to eradicate and is associated with increased mortality and morbidity. Early infection may be easier to eradicate.This is an update of a Cochrane review first published in 2003, and previously updated in 2006, 2009 and 2014.To determine whether antibiotic treatment of early Pseudomonas aeruginosa infection in children and adults with cystic fibrosis eradicates the organism, delays the onset of chronic infection, and results in clinical improvement. To evaluate whether there is evidence that a particular antibiotic strategy is superior to or more cost-effective than other strategies and to compare the adverse effects of different antibiotic strategies (including respiratory infection with other micro-organisms).We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Most recent search: 10 October 2016.We included randomised controlled trials of people with cystic fibrosis, in whom Pseudomonas aeruginosa had recently been isolated from respiratory secretions. We compared combinations of inhaled, oral or intravenous antibiotics with placebo, usual treatment or other combinations of inhaled, oral or intravenous antibiotics. We excluded non-randomised trials, cross-over trials, and those utilising historical controls.Both authors independently selected trials, assessed risk of bias and extracted data.The search identified 60 trials; seven trials (744 participants) with a duration between 28 days and 27 months were eligible for inclusion. Three of the trials are over 10 years old and their results may be less applicable today given the changes in standard treatment. Some of the trials had low numbers of participants and most had relatively short follow-up periods; however, there was generally a low risk of bias from missing data. In most trials it was difficult to blind participants and clinicians to treatment given the interventions and comparators used. Two trials were supported by the manufacturers of the antibiotic used.Evidence from two trials (38 participants) at the two-month time-point showed treatment of early Pseudomonas aeruginosa infection with inhaled tobramycin results in microbiological eradication of the organism from respiratory secretions more often than placebo, odds ratio 0.15 (95% confidence interval (CI) 0.03 to 0.65) and data from one of these trials, with longer follow up, suggested that this effect may persist for up to 12 months.One randomised controlled trial (26 participants) compared oral ciprofloxacin and nebulised colistin versus usual treatment. Results after two years suggested treatment of early infection results in microbiological eradication of Pseudomonas aeruginosa more often than no anti-pseudomonal treatment, odds ratio 0.12 (95% CI 0.02 to 0.79).One trial comparing 28 days to 56 days treatment with nebulised tobramycin solution for inhalation in 88 participants showed that both treatments were effective and well-tolerated, with no notable additional improvement with longer over shorter duration of therapy. However, this trial was not powered to detect non-inferiority or equivalence .A trial of oral ciprofloxacin with inhaled colistin versus nebulised tobramycin solution for inhalation alone (223 participants) failed to show a difference between the two strategies, although it was underpowered to show this. A further trial of inhaled colistin with oral ciprofloxacin versus nebulised tobramycin solution for inhalation with oral ciprofloxacin also showed no superiority of the former, with increased isolation of Stenotrophomonas maltophilia in both groups.A recent, large trial in 306 children aged between one and 12 years compared cycled nebulised tobramycin solution for inhalation to culture-based therapy and also ciprofloxacin to placebo. The primary analysis showed no difference in time to pulmonary exacerbation or proportion of Pseudomonas aeruginosa positive cultures. An analysis performed in this review (not adjusted for age) showed fewer participants in the cycled therapy group with one or more isolates of Pseudomonas aeruginosa, odds ratio 0.51 (95% CI 0.31 to 0.28). Using GRADE, the quality of evidence for outcomes was downgraded to moderate to very low. Downgrading decisions for Pseudomonas aeruginosa eradication and lung function were based on applicability (participants mostly children) and limitations in study design, with imprecision an additional limitation for lung function, growth parameters and adverse effects.We found that nebulised antibiotics, alone or in combination with oral antibiotics, were better than no treatment for early infection with Pseudomonas aeruginosa. Eradication may be sustained for up to two years. There is insufficient evidence to determine whether antibiotic strategies for the eradication of early Pseudomonas aeruginosa decrease mortality or morbidity, improve quality of life, or are associated with adverse effects compared to placebo or standard treatment. Four trials comparing two active treatments have failed to show differences in rates of eradication of Pseudomonas aeruginosa. There have been no published randomised controlled trials that investigate the efficacy of intravenous antibiotics to eradicate Pseudomonas aeruginosa in cystic fibrosis. Overall, there is still insufficient evidence from this review to state which antibiotic strategy should be used for the eradication of early Pseudomonas aeruginosa infection in cystic fibrosis." @default.
• W3164704825 created "2021-06-07" @default.
• W3164704825 creator A5065068630 @default.
• W3164704825 creator A5081128925 @default.
• W3164704825 date "2017-04-25" @default.
• W3164704825 modified "2023-10-15" @default.
• W3164704825 title "Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis" @default.
• W3164704825 cites W1020897773 @default.
• W3164704825 cites W1045435217 @default.
• W3164704825 cites W1521667132 @default.
• W3164704825 cites W1946261316 @default.
• W3164704825 cites W1965776060 @default.
• W3164704825 cites W1969513747 @default.
• W3164704825 cites W1971308436 @default.
• W3164704825 cites W1971558827 @default.
• W3164704825 cites W1972714977 @default.
• W3164704825 cites W1975116926 @default.
• W3164704825 cites W1975909392 @default.
• W3164704825 cites W1977363745 @default.
• W3164704825 cites W1977640666 @default.
• W3164704825 cites W1979329224 @default.
• W3164704825 cites W1979652514 @default.
• W3164704825 cites W1980004985 @default.
• W3164704825 cites W1983565407 @default.
• W3164704825 cites W1987865402 @default.
• W3164704825 cites W1989841457 @default.
• W3164704825 cites W1990312546 @default.
• W3164704825 cites W1990698756 @default.
• W3164704825 cites W1996215008 @default.
• W3164704825 cites W1996565956 @default.
• W3164704825 cites W1996632302 @default.
• W3164704825 cites W1998612252 @default.
• W3164704825 cites W1999729335 @default.
• W3164704825 cites W2000030457 @default.
• W3164704825 cites W2001878860 @default.
• W3164704825 cites W2006634231 @default.
• W3164704825 cites W2006762323 @default.
• W3164704825 cites W2008586082 @default.
• W3164704825 cites W2009812539 @default.
• W3164704825 cites W2010268034 @default.
• W3164704825 cites W2010865348 @default.
• W3164704825 cites W2011932878 @default.
• W3164704825 cites W2013235350 @default.
• W3164704825 cites W2014673448 @default.
• W3164704825 cites W2020334178 @default.
• W3164704825 cites W2023428643 @default.
• W3164704825 cites W2023504710 @default.
• W3164704825 cites W2024545486 @default.
• W3164704825 cites W2029144761 @default.
• W3164704825 cites W2029776332 @default.
• W3164704825 cites W2032147058 @default.
• W3164704825 cites W2033172874 @default.
• W3164704825 cites W2033238263 @default.
• W3164704825 cites W2033895820 @default.
• W3164704825 cites W2034083161 @default.
• W3164704825 cites W2034188416 @default.
• W3164704825 cites W2034964508 @default.
• W3164704825 cites W2037494793 @default.
• W3164704825 cites W2037533817 @default.
• W3164704825 cites W2039936290 @default.
• W3164704825 cites W2040567526 @default.
• W3164704825 cites W2043806515 @default.
• W3164704825 cites W2044393875 @default.
• W3164704825 cites W2046121684 @default.
• W3164704825 cites W2046513922 @default.
• W3164704825 cites W2047992616 @default.
• W3164704825 cites W2049260196 @default.
• W3164704825 cites W2050372767 @default.
• W3164704825 cites W2052197420 @default.
• W3164704825 cites W2053762589 @default.
• W3164704825 cites W2055954317 @default.
• W3164704825 cites W2057496127 @default.
• W3164704825 cites W2058103582 @default.
• W3164704825 cites W2060894544 @default.
• W3164704825 cites W2061909665 @default.
• W3164704825 cites W2064434481 @default.
• W3164704825 cites W2066219884 @default.
• W3164704825 cites W2066416876 @default.
• W3164704825 cites W2068148539 @default.
• W3164704825 cites W2068781163 @default.
• W3164704825 cites W2070458418 @default.
• W3164704825 cites W2073623971 @default.
• W3164704825 cites W2075069205 @default.
• W3164704825 cites W2075072320 @default.
• W3164704825 cites W2075892611 @default.
• W3164704825 cites W2078218308 @default.
• W3164704825 cites W2079413808 @default.
• W3164704825 cites W2080335548 @default.
• W3164704825 cites W2081500562 @default.
• W3164704825 cites W2082612295 @default.
• W3164704825 cites W2083947519 @default.
• W3164704825 cites W2086235445 @default.
• W3164704825 cites W2088123031 @default.
• W3164704825 cites W2088339823 @default.
• W3164704825 cites W2088849723 @default.
• W3164704825 cites W2090180657 @default.
• W3164704825 cites W2090229932 @default.
• W3164704825 cites W2092769213 @default.
• W3164704825 cites W2096464798 @default.
• W3164704825 cites W2097575804 @default.

• next